Department of Medical Biotechnology (2005 - Present)
Clinical Biochemistry
, Tarbiat Modares University,
Clinical Biochemistry
, Tarbiat Modares University,
Laboratory Sciences
, Tehran University of Medical Sciences, tehran, Iran
Research field:
Expert:
Phone:
Address:
Fatemeh Rahbarizadeh received her B. Sc. (1996) from Tehran University of Medical Sciences, Iran. She got her M. Sc (2000) and Ph. D. (2005) majoring in Clinical Biochemistry at Tarbiat Modares University. She finished her Post Doc. (Nanomedicine and Drug Delivery) at 2015 from School of Pharmaceutical Sciences University of Copenhagen, Denmark. She is now working at Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University as associate professor (from 2005). She is the Head of Research and Development Center for Biotechnology of Tarbiat Modares University. Her group consists of 15 researchers including two post-docs and 10 PhD students. Dr F. Rahbarizadeh has been responsible for managing numerous national multidisciplinary projects in CAR T cell therapy, Immunobiotechnology and Nanomedicine. She has published over 90 articles, 3 books, 15 Iranian patents and 1 US patent. She has been received 14 national and international awards. She is the member of Biochemical Society of I.R. Iran, Biotechnological Society of I.R. Iran, Genetic Society of I.R. Iran, Iranian Society of Ethics in Sciences and Technology, and Active Member (no. 365307) of AACR (American Association of Cancer Research).
: Cancer radiotherapy and phototherapy are well-recognized as alternative approaches for chemotherapy-resistant malignancies. Additionally, recently cancer immunotherapy is introduced as a potential therapeutic option for cancer treatment, which has had its ups and downs despite the reported heart-warming outcomes. Nevertheless, it is proved that nanotechnology-facilitated approaches might facilitate the success of these modalities. The nucleolin-targeting aptamer, AS1411, is one of the various aptamers utilized for reducing nanocarriers carrying radiosensitizers and photosensitizers. Recently, the potential applicability of this aptamer has been investigated in cancer immunotherapy. In this review, we, firstly, discussed how aptamer-mediat
PurposeBreast Cancer Stem Cells (BCSCs) resist conventional treatments and cause tumor recurrence. Almost 25% of breast cancers overexpress human epidermal growth factor receptor-2 (HER2). Here we developed a novel multi-targeted nanosystem to speci cally eradicate HER2-positive BCSCs.
The ability of CRISPR/Cas9 to mutate any desired genomic locus is being increasingly explored in the emerging area of cancer immunotherapy. In this respect, current efforts are mostly focused on the use of autologous (i.e. patient-derived) T cells. The autologous approach, however, has drawbacks in terms of manufacturing time, cost, feasibility and scalability that can affect therapeutic outcome or wider clinical application. The use of allogeneic T cells from healthy donors may overcome these limitations. For this strategy to work, the endogenous T cell receptor (TCR) needs to be knocked out in order to reduce off-tumor, graft-versus-host-disease (GvHD). Furthermore, CD52 may be knocked out in the donor T cells, since this leaves them resi
Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. However, CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings. Adverse events such as cytokine release syndrome (CRS), neurotoxicity, graft rejection, on-target off-tumor toxicities, and tumor relapse have tied the rescuing hands of CAR T cell therapies. Moreover, in the case of solid tumor treatment, CAR T cell therapies have not yielded encouraging results mainly due to challenges such as the
Progressive myoclonus epilepsies (PMEs) are a group of disorders embracing myoclonus, seizures, and neurological dysfunctions. Because of the genetic and clinical heterogeneity, a large proportion of PMEs cases have remained molecularly undiagnosed. The present study aimed to determine the underlying genetic factors that contribute to the PME phenotype in an Iranian female patient. We describe a consanguineous Iranian family with autosomal recessive PME that had remained undiagnosed despite extensive genetic and pathological tests. After performing neuroimaging and clinical examinations, due to heterogeneity of PMEs, the proband was subjected to paired-end whole-exome sequencing and the candidate variant was confirmed by Sanger sequencing.
Objective: Immunotherapy with redirected T cells that express a chimeric antigen receptor (CAR) is a promising prospect in cancer treatment. Most CARs use murine-derived single-chain variable fragments (scFvs) as an antigen targeting moiety, which may lead to host immunogenic responses and engineered T cell disappearance. It seems that development of less immunogenic CARs, such as CARs composed of the camelid variable domain of heavy chain antibodies (VHHs) may likely overcome this obstacle. Here, we improved the expression of the VHH-based anti-MUC1 CAR gene construct using a third generation lentiviral vector in primary human T cells and assessed its effect on antigen specific targeting, activation and cytotoxicity of redirected human T c
Chimeric antigen receptor T cell (CAR-T) therapy has so far proved itself as a reliable therapeutic option for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and mantle cell lymphoma (MCL). However, this picture is not as colorful when it comes to the treatment of solid tumors mainly due to the lack of definitive tumor antigens, as well as the immunosuppressive tumor microenvironments and poor CAR-T infiltration. The recent developments in bioinformatics and cell biology, such as single-cell RNA sequencing, have offered silver linings in the subject of tumor antigen discovery. In the current review, we summarize the development of some CAR
Context: Nucleolin is a protein abundantly present in the nucleolus, but its expression on the surface of cells is potentially associated with various types of malignancies. Evidence Acquisition: So far, several nucleolin-targeting strategies, including nucleolin-targeting peptides, anti-nucleolin pseudopeptides, anti-nucleolin antibodies, and the anti-nucleolin aptamers, AS1411, have been developed and investigated in different types of studies. Results: The AS1411 aptamer has been known as the outstanding approach for targeting nucleolin with superior specificity and therapeutic potential in comparison with other targeting strategies. Conclusions: In this review, we highlight different nucleolin-targeting strategies for the targeted deliv
Chimeric antigen receptor (CAR) T cell therapy has offered cancer patients a new alternative therapeutic choice in recent years. This novel type of therapy holds tremendous promise for the treatment of various hematologic malignancies including B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma. However, CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings. Adverse events such as cytokine release syndrome (CRS), neurotoxicity, graft rejection, on-target off-tumor toxicities, and tumor relapse have tied the rescuing hands of CAR T cell therapies. Moreover, in the case of solid tumor treatment, CAR T cell therapies have not yielded encouraging results mainly due to challenges such as the
Nucleolin is a protein abundantly present in the nucleolus, but its expression on the surface of cells is potentially associated with various types of malignancies. So far, several nucleolin-targeting strategies, including the nucleolin-targeting peptide, anti-nucleolin pseudopeptides, anti-nucleolin antibodies, and the anti-nucleolin aptamer, AS1411, have been developed and investigated in different types of studies. The AS1411 aptamer has been known as the outstanding approach for targeting nucleolin with superior specificity and therapeutic potential in comparison with other targeting strategies. In this review, we highlight different nucleolintargeting strategies for the targeted delivery of chemotherapeutic drugs, proteins with therape
Objective: The purpose of this study was to develop multivalent antibody constructs via grafting anti-HER2 antibodies, including Herceptin and oligoclonal-variable domain of heavy chain antibodies (VHHs), onto liposome membranes to enhance antibody activity and compare their effect on phospholipase C (PLC) signaling pathway with control. Materials and Methods: In this experimental study, SKBR3 and BT-474 cell lines as HER2 positive and MCF10A cell line as normal cell were screened with anti-HER2 antibodies, including constructs of multivalent liposomal antibody developed with Herceptin and anti-HER2 oligoclonal-VHHs. To confirm the accuracy of the study, immunofluorescent assay, migration assay and immuno-liposome binding ability to HER2 we
no record found